Literature DB >> 16772149

Diagnosis of hyperandrogenism: clinical criteria.

Bulent O Yildiz1.   

Abstract

Hyperandrogenism or androgen excess is a common endocrine disorder of women of reproductive-age, with a prevalence of 5-10%. The majority of patients with hyperandrogenism will have polycystic ovary syndrome. Hyperandrogenism presents a complex diagnostic challenge for both the practicing physician and the clinical investigator. Clinical manifestations of hyperandrogenism include hirsutism, acne, androgenic alopecia, and virilization. Hirsutism, defined as excessive growth of terminal hair in women in a male-like pattern, is the most commonly used clinical diagnostic criterion of hyperandrogenism. The presence of hirsutism is usually determined by using a standardized scoring system of hair growth. Depending on the definition, hirsutism is present in up to 80% of patients with hyperandrogenism. Acne and androgenic alopecia are other common androgenic skin changes, and might be observed without hirsutism in some hyperandrogenic women. However, isolated presence of any of these manifestations is not used as a diagnostic criterion for hyperandrogenism. Virilization is a relatively uncommon feature of hyperandrogenism, and its presence often suggests an androgen-producing tumor. A thorough history and a focused clinical examination are extremely helpful in diagnostic evaluation of patients with suspected hyperandrogenism.

Entities:  

Mesh:

Year:  2006        PMID: 16772149     DOI: 10.1016/j.beem.2006.02.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  17 in total

Review 1.  Dermatologic manifestations of endocrine disorders.

Authors:  Michael Lause; Alisha Kamboj; Esteban Fernandez Faith
Journal:  Transl Pediatr       Date:  2017-10

2.  Importance of Dehydroepiandrosterone Sulfate Assessment with Special Attention for Adrenal Tumours and Arterial Hypertension.

Authors:  V Matulevicius; V Urbanavicius; S Lukosevicius; I Banisauskaite; G Donielaite; A Galkine
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

3.  Polycystic ovary syndrome is linked with the fat mass obesity (FTO) gene variants rs17817449 and rs1421085 in western Saudi Arabia.

Authors:  Sherin Bakhashab; Asma A Batarfi; Najlaa Filimban; Osama S Bajouh; Ashraf Dallol; Mohammed H Alqahtani
Journal:  Bioinformation       Date:  2021-11-30

4.  Virilizing adrenocortical oncocytoma in a child: a case report.

Authors:  Yeon-Jung Lim; Se-Min Lee; Jae-Hun Shin; Hyun-Chul Koh; Young-Ho Lee
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

5.  THE RARE CASE OF MIXED GONADAL DYSGENESIS, MOSAIC KARYOTYPE, PETROCLIVAL MENINGIOMA AND IDIOPATHIC HYPERDEHYDROEPIANDROSTERONISM.

Authors:  V Matulevicius; V Urbanavicius; S Lukosevicius; L Ciaplinskiene; R Ostrauskas
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

6.  Severe hyperandrogenism due to ovarian hyperthecosis in a young woman.

Authors:  Alpesh Goyal; Rakhi Malhotra; Vidushi Kulshrestha; Garima Kachhawa
Journal:  BMJ Case Rep       Date:  2019-12-17

Review 7.  Insulin resistance and skin diseases.

Authors:  Maddalena Napolitano; Matteo Megna; Giuseppe Monfrecola
Journal:  ScientificWorldJournal       Date:  2015-04-21

8.  Heterosexual precocity: rare manifestation of virilizing adrenocortical oncocytoma.

Authors:  Sridhar Subbiah; Uma Nahar; Ram Samujh; Anil Bhansali
Journal:  Ann Saudi Med       Date:  2013 May-Jun       Impact factor: 1.526

9.  Epidemiology of polycystic ovary syndrome: a cross sectional study of university students at An-Najah national university-Palestine.

Authors:  Samar Musmar; Asma Afaneh; Hafsa Mo'alla
Journal:  Reprod Biol Endocrinol       Date:  2013-05-20       Impact factor: 5.211

10.  Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare.

Authors:  Ligia Gabrielli; Estela M I Aquino
Journal:  Reprod Biol Endocrinol       Date:  2012-11-22       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.